FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296039304> ?p ?o ?g. }

• W4296039304 endingPage "613" @default.
• W4296039304 startingPage "601" @default.
• W4296039304 abstract "Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) are frequently poly-medicated due to age-related and androgen deprivation therapy (ADT)-derived comorbidities. In high-risk patients, androgen receptor inhibitors (ARIs) have shown to delay disease progression; however, drug-drug interactions (DDIs) with preexisting medications may impact the therapeutic effect and safety of these and of the ARIs themselves.We review the potential comorbidity burden of nmCRPC patients on the basis of epidemiologic studies on age-related comorbidities, the impact of ADT and specific studies analyzing this topic. Using the DDIs compendia Lexicomp® and Drugs.com®, we provide a scenario of the potential DDIs between common mediations used to treat these comorbidities and the three currently available ARIs: apalutamide, enzalutamide and darolutamide.In high-risk nmCRPC patients to be treated with an ARI, careful multidisciplinary evaluation of potential DDIs is a fundamental component in the clinical-decision making. The lower potential for DDIs, the lower need for dose adjustment or change of current comedications and of patient monitoring, and safer introduction of new comedications. To optimize this step, an effort is still needed to determine the clinical relevance of DDIs and to harmonize their definition and classification among the different compendia.Prostate cancer is one of the most common cancers in men. It is normally diagnosed at age 60 or above, so these men are usually taking medications to treat age-related conditions (e.g. hypertension, diabetes, high cholesterol, etc.).One of the main treatments for prostate cancer is ‘androgen deprivation therapy’ (ADT), a hormone treatment that reduces androgens level. This is because the growth of prostate cancer cells is dependent on male sex hormones called androgens. Despite ADT helping keep the cancer controlled for a time, it increases the risk for adverse events that may need new medications. Consequently, men with prostate cancer usually take multiple medications.After some years, ADT may not be enough to control the prostate cancer. A type of medication called ‘androgen receptor inhibitors’ (ARIs), which prevent the androgen entering the cell, are helpful at this stage, especially the second-generation ones: apalutamide, enzalutamide, and darolutamide. The problem is that these ARIs usually interact with other medications already taken by patients, an effect called ‘drug–drug interaction.’ When this happens, the ARI (the interaction ‘perpetrator’) may modify the effectiveness of other medications (the ‘victims’) and/or cause unexpected effects. Consequently, the conditions being treated by these medications may not be properly controlled, which may pose a risk to the patient’s health. Thus, when starting treatment with a second-generation ARI, it is crucial to consider all possible interactions with the medications taken. The fewer potential interactions the ARI has, the easier it is to properly control other common conditions in prostate cancer patients." @default.
• W4296039304 created "2022-09-17" @default.
• W4296039304 creator A5043649338 @default.
• W4296039304 creator A5064019554 @default.
• W4296039304 creator A5065073093 @default.
• W4296039304 creator A5091309316 @default.
• W4296039304 date "2022-09-02" @default.
• W4296039304 modified "2023-10-14" @default.
• W4296039304 title "Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions" @default.
• W4296039304 cites W1904433804 @default.
• W4296039304 cites W1905297666 @default.
• W4296039304 cites W1967055099 @default.
• W4296039304 cites W1983660130 @default.
• W4296039304 cites W1985995385 @default.
• W4296039304 cites W1991833417 @default.
• W4296039304 cites W1993023211 @default.
• W4296039304 cites W1999742630 @default.
• W4296039304 cites W2009427808 @default.
• W4296039304 cites W2010427019 @default.
• W4296039304 cites W2013135869 @default.
• W4296039304 cites W2026345582 @default.
• W4296039304 cites W2029963458 @default.
• W4296039304 cites W2030521036 @default.
• W4296039304 cites W2046817994 @default.
• W4296039304 cites W2072036446 @default.
• W4296039304 cites W2076485417 @default.
• W4296039304 cites W2098998490 @default.
• W4296039304 cites W2099037568 @default.
• W4296039304 cites W2103714496 @default.
• W4296039304 cites W2104412007 @default.
• W4296039304 cites W2107053205 @default.
• W4296039304 cites W2107660570 @default.
• W4296039304 cites W2116216323 @default.
• W4296039304 cites W2119283349 @default.
• W4296039304 cites W2119528561 @default.
• W4296039304 cites W2120767567 @default.
• W4296039304 cites W2123813397 @default.
• W4296039304 cites W2126374659 @default.
• W4296039304 cites W2135106949 @default.
• W4296039304 cites W2135492571 @default.
• W4296039304 cites W2148659963 @default.
• W4296039304 cites W2192798466 @default.
• W4296039304 cites W2261870911 @default.
• W4296039304 cites W2345092591 @default.
• W4296039304 cites W2511251225 @default.
• W4296039304 cites W2600371642 @default.
• W4296039304 cites W2605129537 @default.
• W4296039304 cites W2751952555 @default.
• W4296039304 cites W2792086148 @default.
• W4296039304 cites W2801520839 @default.
• W4296039304 cites W2804807399 @default.
• W4296039304 cites W2810806599 @default.
• W4296039304 cites W2883499584 @default.
• W4296039304 cites W2913767564 @default.
• W4296039304 cites W2954405419 @default.
• W4296039304 cites W2955010960 @default.
• W4296039304 cites W2977338802 @default.
• W4296039304 cites W2978713040 @default.
• W4296039304 cites W2995389688 @default.
• W4296039304 cites W2996439339 @default.
• W4296039304 cites W2998390711 @default.
• W4296039304 cites W3002613900 @default.
• W4296039304 cites W3018168093 @default.
• W4296039304 cites W3018908320 @default.
• W4296039304 cites W3030001291 @default.
• W4296039304 cites W3031020438 @default.
• W4296039304 cites W3031459577 @default.
• W4296039304 cites W3084238852 @default.
• W4296039304 cites W3087485153 @default.
• W4296039304 cites W3092471450 @default.
• W4296039304 cites W3120744713 @default.
• W4296039304 cites W3122991392 @default.
• W4296039304 cites W3133065864 @default.
• W4296039304 cites W3137128961 @default.
• W4296039304 cites W3170281314 @default.
• W4296039304 cites W3212784804 @default.
• W4296039304 cites W3213518726 @default.
• W4296039304 cites W4206232885 @default.
• W4296039304 cites W4213196409 @default.
• W4296039304 cites W4280652722 @default.
• W4296039304 doi "https://doi.org/10.1080/17425255.2022.2122812" @default.
• W4296039304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36111393" @default.
• W4296039304 hasPublicationYear "2022" @default.
• W4296039304 type Work @default.
• W4296039304 citedByCount "2" @default.
• W4296039304 countsByYear W42960393042023 @default.
• W4296039304 crossrefType "journal-article" @default.
• W4296039304 hasAuthorship W4296039304A5043649338 @default.
• W4296039304 hasAuthorship W4296039304A5064019554 @default.
• W4296039304 hasAuthorship W4296039304A5065073093 @default.
• W4296039304 hasAuthorship W4296039304A5091309316 @default.
• W4296039304 hasBestOaLocation W42960393041 @default.
• W4296039304 hasConcept C121608353 @default.
• W4296039304 hasConcept C126322002 @default.
• W4296039304 hasConcept C143998085 @default.
• W4296039304 hasConcept C2776551883 @default.
• W4296039304 hasConcept C2777899217 @default.
• W4296039304 hasConcept C2779134260 @default.

• next